CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients.
作者信息
Cassinat Bruno, Verger Emmanuelle, Maslah Nabih, Gauthier Nicolas, Vainchenker William, Giraudier Stéphane, Kiladjian Jean-Jacques
机构信息
AP-HP, Laboratoire de Biologie Cellulaire, Hôpital Saint-Louis, Paris
Université de Paris, U1131 INSERM, Paris
出版信息
Haematologica. 2021 Mar 1;106(3):863-864. doi: 10.3324/haematol.2020.252643.
Abstract
摘要
相似文献
1
CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients.CCND2突变在BCR-ABL1阴性骨髓增殖性肿瘤患者中是罕见事件。
Haematologica. 2021 Mar 1;106(3):863-864. doi: 10.3324/haematol.2020.252643.
2
A link between the driver mutations and dysregulated apoptosis in BCR-ABL1 negative myeloproliferative neoplasms.驱动基因突变与BCR-ABL1阴性骨髓增殖性肿瘤中凋亡失调之间的联系。
J Immunoassay Immunochem. 2016;37(4):331-45. doi: 10.1080/15321819.2016.1152276.
3
Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.三例骨髓增殖性肿瘤患者中同时存在BCR-ABL1易位和JAK2(V617F)突变
Diagn Mol Pathol. 2012 Sep;21(3):176-83. doi: 10.1097/PDM.0b013e318246975e.
4
A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm.非典型骨髓增殖性肿瘤中，BCR-ABL1之前出现的CALR突变。
N Engl J Med. 2015 Feb 12;372(7):688-90. doi: 10.1056/NEJMc1413718.
5
Mutational analysis of SH2B3 in Korean patients with BCR-ABL1 negative myeloproliferative neoplasm.韩国BCR-ABL1阴性骨髓增殖性肿瘤患者中SH2B3的突变分析
Ann Lab Med. 2016 Jan;36(1):67-9. doi: 10.3343/alm.2016.36.1.67.
6
BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.BCR-ABL阴性骨髓增殖性肿瘤：相关分子机制综述
Histol Histopathol. 2015 Feb;30(2):151-61. doi: 10.14670/HH-30.151. Epub 2014 Sep 5.
7
mutations in atypical chronic myeloid leukemia: a report of two cases.非典型慢性髓性白血病中的突变：两例报告
Leuk Lymphoma. 2023 Oct;64(10):1730-1732. doi: 10.1080/10428194.2023.2232495. Epub 2023 Jul 12.
8
Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.并发JAK2阳性骨髓增殖性疾病和慢性粒细胞白血病：一种新的实体？一例病例报告并文献复习
J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619832322. doi: 10.1177/2324709619832322.
9
CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.阿根廷BCR-ABL1阴性骨髓增殖性肿瘤患者中CALR、JAK2和MPL的突变状态
Hematology. 2018 May;23(4):208-211. doi: 10.1080/10245332.2017.1385891. Epub 2017 Oct 9.
10
[Investigation of Laboratory and Clinical Feature in the Patients with Myeloproliferative Neoplasm Co-expression of BCR-ABL1 and JAK2 V617F].[骨髓增殖性肿瘤患者中BCR-ABL1和JAK2 V617F共表达的实验室及临床特征研究]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Aug;29(4):1236-1241. doi: 10.19746/j.cnki.issn.1009-2137.2021.04.033.
引用本文的文献
1
Conserved helical motifs in the IKZF1 disordered region mediate NuRD interaction and transcriptional repression.IKZF1无序区域中保守的螺旋基序介导NuRD相互作用和转录抑制。
Blood. 2025 Jan 23;145(4):422-437. doi: 10.1182/blood.2024024787.
2
Atypical CML: diagnosis and treatment.非典型慢性髓性白血病：诊断与治疗。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):476-482. doi: 10.1182/hematology.2023000448.
3
Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition.单细胞分析揭示了 MDM2 抑制后 TP53 突变克隆的选择。
Blood Adv. 2022 May 10;6(9):2813-2823. doi: 10.1182/bloodadvances.2021005867.
4
Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.骨髓增殖性肿瘤中的下一代测序。过去的经验教训以及用作预后和治疗反应预测指标的前景。
Cancers (Basel). 2020 Aug 6;12(8):2194. doi: 10.3390/cancers12082194.
本文引用的文献
1
Prognostic role of cyclin D2/D3 in multiple human malignant neoplasms: A systematic review and meta-analysis.Cyclin D2/D3 在多种人类恶性肿瘤中的预后作用：系统评价和荟萃分析。
Cancer Med. 2019 Jun;8(6):2717-2729. doi: 10.1002/cam4.2152. Epub 2019 Apr 5.
2
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.MIPSS70：原发性骨髓纤维化移植年龄患者的突变增强国际预后评分系统。
J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9.
3
Recurrent cyclin D2 mutations in myeloid neoplasms.髓系肿瘤中反复出现的细胞周期蛋白D2突变
Leukemia. 2017 Sep;31(9):2005-2008. doi: 10.1038/leu.2017.195. Epub 2017 Jun 20.
4
Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms.靶向二代测序鉴定出三阴性骨髓增殖性肿瘤中的新突变。
Med Oncol. 2017 May;34(5):83. doi: 10.1007/s12032-017-0944-z. Epub 2017 Apr 7.
5
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.在患有t(8;21)(q22;q22)急性髓系白血病的成年患者中，CCND1和CCND2基因的突变是常见事件。
Leukemia. 2017 Jun;31(6):1278-1285. doi: 10.1038/leu.2016.332. Epub 2016 Nov 15.
6
The genomic landscape of core-binding factor acute myeloid leukemias.核心结合因子急性髓系白血病的基因组格局
Nat Genet. 2016 Dec;48(12):1551-1556. doi: 10.1038/ng.3709. Epub 2016 Oct 31.
7
De novo CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome.导致 cyclin D2 稳定的 CCND2 基因突变引发巨脑-多小脑回-多指-脑积水综合征。
Nat Genet. 2014 May;46(5):510-515. doi: 10.1038/ng.2948. Epub 2014 Apr 6.
Zotero 插件